All In Biotech

Investigational drug · Phase 2

Umbilical Cord Mesenchymal Stem Cells

Also called: Mesenchymal stromal cells, Allogeneic Mesenchymal Stem Cells

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Nephropathy Type 2, Ischemic Stroke, Cerebral Palsy.

Phase 2

Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

477

Any phase or sponsor naming "Umbilical Cord Mesenchymal Stem Cells"

First trial start

2021

Oct 13, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Umbilical Cord Mesenchymal Stem Cells", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diabetic Nephropathy Type 2
  • Ischemic Stroke
  • Cerebral Palsy
  • Pathologic Processes

Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Umbilical Cord Mesenchymal Stem Cells" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14,866 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.